Universität zu Köln

Borchmann, Peter and Engert, Andreas (2010). The Past: What We Have Learned in the Last Decade. Hematol.-Am. Soc. Hematol. Educ. Program. S. 101 - 108. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1520-4383

Full text not available from this repository.

Abstract

Hodgkin lymphoma (HL) has become a curable malignancy for most patients during the last decades. However, many controversies still exist on the optimal strategy of how to cure our patients. The key question is how to balance the risks and toxicities of chemotherapy and radiotherapy against the need for a definite treatment for early or advanced-stage HL patients. However, although many studies have been conducted and reported during the past decade, interpretation of their results and treatment recommendations might vary significantly in different countries. For example, early-stage HL might be divided into two different subgroups: early favorable and early unfavorable or not. Treatment of early-stage HL might include radiotherapy (combined modality) or not. Depending on the extent of radiotherapy, the schedule and number of chemotherapy cycles are also questioned. For advanced-stage HL, the situation is not much different. Compared with ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine), the more aggressive escalated BEACOPP regimen (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) is highly effective, but also raises concern due to excessive toxicity. Thus, there is a controversy about the standard of care for advanced HL patients. Because no mature results comparing these approaches with each other are currently available, it remains our duty to share the preliminary information with our patients and to figure out the most appropriate individual treatment strategy. Of course, the discussion of these issues is influenced by experiences and preferences. In contrast, in this article, we will try to focus on the available scientific evidence regarding the first-line treatment of HL. Of course, focusing on the last decade necessarily exclude the most recent results from ongoing studies. Thus, even though this article comprises treatment recommendations for HL patients, the best treatment certainly still is within properly designed prospective clinical trials.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-491497
DOI:	10.1182/asheducation-2010.1.101
Journal or Publication Title:	Hematol.-Am. Soc. Hematol. Educ. Program
Page Range:	S. 101 - 108
Date:	2010
Publisher:	AMER SOC HEMATOLOGY
Place of Publication:	WASHINGTON
ISSN:	1520-4383
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ADVANCED HODGKINS-DISEASE; POSITRON-EMISSION-TOMOGRAPHY; INVOLVED-FIELD RADIOTHERAPY; ABVD PLUS RADIOTHERAPY; RANDOMIZED-TRIAL; RADIATION-THERAPY; DOSE-ESCALATION; STANFORD-V; STAGE-I; CHEMOTHERAPY Multiple languages Education, Scientific Disciplines; Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/49149